1 |
http://en.wikipedia.org/wiki/Silibinin
|
2 |
Ka, S. O., K. A. Kim, K. B. Kwon, J. W. Park, and B. H. Park (2009) Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway. Int. J. Mol. Med. 23: 633-7.
|
3 |
Abete, I., A. Astrup, J. A. Martinez, I. Thorsdottir, and M. A. Zulet (2010) Obesity and the metabolic syndrome: role of different dietary macronutrient distribution patterns and specific nutritional components on weight loss and maintenance. Nutr. Rev. 68: 214-31.
DOI
ScienceOn
|
4 |
Mathieu, P., I. Lemieux, and J. P. Despres (2010) Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther. 87: 407-16.
DOI
ScienceOn
|
5 |
Krecman, V., N. Skottova, D. Walterova, J. Ulrichova, and V. Simanek (1998) Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med. 64: 138-42.
DOI
|
6 |
Kobalava, Z. D., S. V. Villevalde, and K. V. Isikova (2009) The role of adiponectin in development and progression of cardiovascular diseases. Kardiologiia 49:51-8.
|
7 |
Guzik, T. J., D. Mangalat, and R. Korbut (2006) Adipocytokines-novel link between inflammation and vascular function?. J. Physiol. Pharmacol. 57: 505-28.
|
8 |
Stofkova A. (2009) Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr. Regul. 43: 157-68.
|
9 |
Cheung, C. W., N. Gibbons, D. W. Johnson, and D. L. Nicol (2010) Silibinin, a promising new treatment for cancer. Anticancer Agents Med. Chem. 10: 186-95.
DOI
ScienceOn
|
10 |
Gazak, R., D. Walterova, and V. Kren (2007) Silybin and silymarin-new and emerging applications in medicine. Curr. Med. Chem. 14: 315-38.
DOI
ScienceOn
|
11 |
Flora, K., M. Hahn, H. Rosen, and K. Benner (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 93: 139-43.
DOI
ScienceOn
|